150 related articles for article (PubMed ID: 37012318)
1. Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation.
Frenel JS; Lusque A; Delaloge S; Ferrero JM; Bachelot T; Desmoulins I; Levy C; Eymard JC; Gonçalves A; Patsouris A; Reynier MAM; Thery MJ; Petit T; Cabel L; Uwer L; Debled M; Chevrot M; Mailliez A; Jacot W; de La Motte Rouge T
Br J Cancer; 2023 Jun; 128(11):2072-2080. PubMed ID: 37012318
[TBL] [Abstract][Full Text] [Related]
2. Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database.
Mailliez A; D'Hondt V; Lusque A; Caron O; Cabel L; Goncalves A; Debled M; Gladieff L; Ferrero JM; Petit T; Mouret-Reynier MA; Eymard JC; Levy C; Uwer L; Leheurteur M; Desmoulins I; Bachelot T; Frenel JS; de la Motte Rouge T; Simon G; Jacot W; Delaloge S
Int J Cancer; 2023 Mar; 152(5):921-931. PubMed ID: 36161271
[TBL] [Abstract][Full Text] [Related]
3. Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
Quek RGW; Mardekian J
Adv Ther; 2019 Mar; 36(3):708-720. PubMed ID: 30656571
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study.
O'Shaughnessy J; Brezden-Masley C; Cazzaniga M; Dalvi T; Walker G; Bennett J; Ohsumi S
Breast Cancer Res; 2020 Oct; 22(1):114. PubMed ID: 33109210
[TBL] [Abstract][Full Text] [Related]
5. A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status.
Collins JM; Nordstrom BL; McLaurin KK; Dalvi TB; McCutcheon SC; Bennett JC; Murphy BR; Singhal PK; McCrea C; Shinde R; Briceno JM
Oncol Ther; 2021 Dec; 9(2):575-589. PubMed ID: 34308518
[TBL] [Abstract][Full Text] [Related]
6. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.
Gelmon KA; Fasching PA; Couch FJ; Balmaña J; Delaloge S; Labidi-Galy I; Bennett J; McCutcheon S; Walker G; O'Shaughnessy J;
Eur J Cancer; 2021 Jul; 152():68-77. PubMed ID: 34087573
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations.
Jacot W; Lusque A; Vicier C; Mailliez A; de La Motte Rouge T; Cabel L; Levy C; Patsouris A; Desmoulins I; Uwer L; Thery JC; Robain M; Caron O; Tredan O; Filleron T; Frenel JS; Delaloge S
Br J Cancer; 2022 Nov; 127(11):1963-1973. PubMed ID: 36207609
[TBL] [Abstract][Full Text] [Related]
8. Subtype-Specific Survival of Young Women with Breast Cancer and Its Interaction with the Germline BRCA Status.
Hage AM; Gebert P; Blohmer JU; Hedayati E; Speiser D; Karsten MM
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398129
[TBL] [Abstract][Full Text] [Related]
9. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.
Jacquet E; Lardy-Cléaud A; Pistilli B; Franck S; Cottu P; Delaloge S; Debled M; Vanlemmens L; Leheurteur M; Guizard AV; Laborde L; Uwer L; Jacot W; Berchery D; Desmoulins I; Ferrero JM; Perrocheau G; Courtinard C; Brain E; Chabaud S; Robain M; Bachelot T
Eur J Cancer; 2018 May; 95():93-101. PubMed ID: 29655061
[TBL] [Abstract][Full Text] [Related]
10. Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.
Hodgson D; Lai Z; Dearden S; Barrett JC; Harrington EA; Timms K; Lanchbury J; Wu W; Allen A; Senkus E; Domchek SM; Robson M
Ann Oncol; 2021 Dec; 32(12):1582-1589. PubMed ID: 34500047
[TBL] [Abstract][Full Text] [Related]
11. Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program.
Le Du F; Carton M; Bachelot T; Saghatchian M; Pistilli B; Brain E; Loirat D; Vanlemmens L; Vermeulin T; Emile G; Gonçalves A; Ung M; Robert M; Jaffre A; Desmoulins I; Jouannaud C; Uwer L; Marc Ferrero J; Mouret-Reynier MA; Jacot W; Chevrot M; Delaloge S; Diéras V
Oncologist; 2023 Oct; 28(10):e867-e876. PubMed ID: 37589218
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.
Kriege M; Seynaeve C; Meijers-Heijboer H; Collee JM; Menke-Pluymers MB; Bartels CC; Tilanus-Linthorst MM; Blom J; Huijskens E; Jager A; van den Ouweland A; van Geel B; Hooning MJ; Brekelmans CT; Klijn JG
J Clin Oncol; 2009 Aug; 27(23):3764-71. PubMed ID: 19564533
[TBL] [Abstract][Full Text] [Related]
13. First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER.
Tripathy D; Kaufman PA; Brufsky AM; Mayer M; Yood MU; Yoo B; Quah C; Yardley D; Rugo HS
Oncologist; 2013; 18(5):501-10. PubMed ID: 23652380
[TBL] [Abstract][Full Text] [Related]
14. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
Robson ME; Tung N; Conte P; Im SA; Senkus E; Xu B; Masuda N; Delaloge S; Li W; Armstrong A; Wu W; Goessl C; Runswick S; Domchek SM
Ann Oncol; 2019 Apr; 30(4):558-566. PubMed ID: 30689707
[TBL] [Abstract][Full Text] [Related]
15. Niraparib for Advanced Breast Cancer with Germline
Turner NC; Balmaña J; Poncet C; Goulioti T; Tryfonidis K; Honkoop AH; Zoppoli G; Razis E; Johannsson OT; Colleoni M; Tutt AN; Audeh W; Ignatiadis M; Mailliez A; Trédan O; Musolino A; Vuylsteke P; Juan-Fita MJ; Macpherson IRJ; Kaufman B; Manso L; Goldstein LJ; Ellard SL; Láng I; Jen KY; Adam V; Litière S; Erban J; Cameron DA;
Clin Cancer Res; 2021 Oct; 27(20):5482-5491. PubMed ID: 34301749
[TBL] [Abstract][Full Text] [Related]
16. Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database.
Annonay M; Gauquelin L; Geiss R; Ung M; Cristol-Dalstein L; Mouret-Reynier MA; Goncalves A; Abadie-Lacourtoisie S; Francois E; Perrin C; Le Fel J; Lorgis V; Servent V; Uwer L; Jouannaud C; Leheurteur M; Joly F; Campion L; Courtinard C; Villacroux O; Petit T; Soubeyran P; Terret C; Bellera C; Brain E; Delaloge S
Breast; 2021 Dec; 60():138-146. PubMed ID: 34624756
[TBL] [Abstract][Full Text] [Related]
17. Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens.
Cabel L; Carton M; Cheaib B; Pierga JY; Dalenc F; Mailliez A; Levy C; Jacot W; Debled M; Leheurteur M; Desmoulins I; Lefeuvre C; Gonçalves A; Uwer L; Ferrero JM; Eymard JC; Petit T; Mouret-Reynier MA; Perrocheau G; Piot I; Pérol D; Simon G; Lerebours F
Breast Cancer Res Treat; 2019 Jan; 173(2):397-406. PubMed ID: 30357526
[TBL] [Abstract][Full Text] [Related]
18. Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial.
Lee KH; Sohn J; Goodwin A; Usari T; Lanzalone S; Im SA; Kim SB
Cancer Res Treat; 2021 Oct; 53(4):1084-1095. PubMed ID: 33781053
[TBL] [Abstract][Full Text] [Related]
19. Real-world multi-country study of
Lux MP; Lewis K; Rider A; Niyazov A
Future Oncol; 2022 Mar; 18(9):1089-1101. PubMed ID: 35098723
[TBL] [Abstract][Full Text] [Related]
20. Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.
Balmaña J; Fasching PA; Couch FJ; Delaloge S; Labidi-Galy I; O'Shaughnessy J; Park YH; Eisen AF; You B; Bourgeois H; Gonçalves A; Kemp Z; Swampillai A; Jankowski T; Sohn JH; Poddubskaya E; Mukhametshina G; Aksoy S; Timcheva CV; Park-Simon TW; Antón-Torres A; John E; Baria K; Gibson I; Gelmon KA;
Breast Cancer Res Treat; 2024 Apr; 204(2):237-248. PubMed ID: 38112922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
